MIRA PHARMACEUTICALS, INC. COMMON STOCK (NASDAQ: MIRA)

MIRA PHARMACEUTICALS, INC. COMMON STOCK

NASDAQ: MIRA (MIRA Pharmaceuticals, Inc.)

Last update: 25 Aug, 12:58AM

1.43

0.03 (2.14%)

Add to watchlist

Previous Close	1.40
Open	1.40
Volume	171,063
Avg. Volume (3M)	1,330,335
Market Cap	27,269,098

Price / Book

44.84

52 Weeks Range

0.730 (-48%) — 2.70 (88%)

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bullish	Bearish
	Drug Manufacturers - General (Global)	Bullish	Bearish
Stock	MIRA Pharmaceuticals, Inc.	Mixed	Mixed

AIStockmoo Score

1.1

Analyst Consensus	2.0
Insider Activity	NA
Price Volatility	-2.0
Technical Moving Averages	5.0
Technical Oscillators	-0.5
Average	1.13

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
MIRA	27 M	-	-	44.84
AMRN	400 M	-	-	0.740
SCLXW	-	-	-	-
AZN	236 B	2.08%	28.44	5.80
SNY	118 B	4.58%	16.37	1.49
AMGN	159 B	3.17%	24.20	19.78

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Sector	Healthcare
Industry	Drug Manufacturers - General
% Held by Insiders	19.68%
% Held by Institutions	5.60%

Ownership

Name	Date	Shares Held
Suncoast Equity Management	30 Jun 2025	103,289
First American Bank	30 Jun 2025	20,000
Cary Street Partners Financial Llc	30 Jun 2025	10,000

No data within this time range.

Date	Type	Details
30 Sep 2025	Announcement	MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
22 Sep 2025	Announcement	MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
16 Sep 2025	Announcement	MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
12 Sep 2025	Announcement	MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
19 Aug 2025	Announcement	MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
12 Aug 2025	Announcement	MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
30 Jul 2025	Announcement	MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
29 Jul 2025	Announcement	MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
11 Jul 2025	Announcement	MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Total Debt/Equity (MRQ)	0.04%
Current Ratio (MRQ)	12.85
Operating Cash Flow (TTM)	-6.14 M
Levered Free Cash Flow (TTM)	-3.26 M

Return on Assets (TTM)	-193.30%
Return on Equity (TTM)	-355.82%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)